Captrust Financial Advisors Adaptimmune Therapeutics PLC Transaction History
Captrust Financial Advisors
- $43.1 Billion
- Q2 2025
A detailed history of Captrust Financial Advisors transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Captrust Financial Advisors holds 79,083 shares of ADAP stock, worth $3,954. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,083
Previous 80,609
1.89%
Holding current value
$3,954
Previous $16,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ADAP
# of Institutions
68Shares Held
116MCall Options Held
10.3KPut Options Held
0-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$1.37 Million0.57% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$1.19 Million0.26% of portfolio
-
Two Seas Capital LP Rye, NY22.6MShares$1.13 Million0.1% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$853,9880.34% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.81MShares$240,4832.66% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $8.17M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...